Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cited by (1,008)

Items 801–900 of 1,008

1. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine
   Wakako Furuyama, Kyle Shifflett, Amanda N. Pinski, Amanda J. Griffin, Friederike Feldmann, Atsushi Okumura, Tylisha Gourdine, Allen Jankeel, Jamie Lovaglio, Patrick W. Hanley et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
2. Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena
   Arghadip Samaddar, Malika Grover, Vijaya Lakshmi Nag · 2020 · Frontiers in Pharmacology
3. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
   Wen Su, Sin Fun Sia, Aaron J. Schmitz, Traci L. Bricker, Tyler N. Starr, Allison J. Greaney, Jackson S. Turner, Bassem M. Mohammed, Zhuoming Liu, Ka Tim Choy et al. · 2021 · mBio
4. Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
   Ashley Gray, Rachel Martin‐Blais, Nicole H. Tobin, Yan Wang, Sarah L Brooker, Fan Li, Adva Gadoth, Julie E. Elliott, Emmanuelle Faure-Kumar, Megan Halbrook et al. · 2021 · PLoS ONE
5. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens
   Ryuta Uraki, Masaki Imai, Mutsumi Ito, Hiroaki Shime, Mizuyu Odanaka, Moe Okuda, Yoshihiro Kawaoka, Sayuri Yamazaki · 2021 · PLoS Pathogens
6. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern
   B. Kovačech, L. Fialova, P. Filipcik, R. Škrabana, M. Zilkova, Natalia Paulenka-Ivanovova, A. Kováč, Denisa Palova, G. Rolkova, K. Tomková et al. · 2022 · EBioMedicine
7. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance
   Jia Zou, Li Li, Peiyi Zheng, Wenhua Liang, Siyi Hu, Shuaixiang Zhou, Yanqun Wang, Jincun Zhao, Daopeng Yuan, Lu Liu et al. · 2022 · Journal of Clinical Investigation
8. Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C—Can We Match the Puzzle?
   Snezhina Lazova, Yulia Dimitrova, Diana M. Hristova, Iren S. Tzotcheva, Tsvetelina Veselinova Velikova · 2022 · Antibodies
9. The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
   Xiaolong Tian, Xiaoyi Zhu, Wenping Song, Zhenlin Yang, Yanling Wu, Tianlei Ying · 2022 · Emerging Microbes & Infections
10. De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV‐2 spike receptor binding domain (RBD)
    V. Boorla, Ratul Chowdhury, Ranjani Ramasubramanian, Brandon Ameglio, Rahel Frick, Jeffrey J. Gray, C. Maranas · 2022 · Proteins: Structure, Function, and Bioinformatics
11. Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents
    Zhiqing Li, Xiaosu Chen, Junyan Dan, Tianju Hu, Ye Hu, Shuxun Liu, Yangyang Chai, Yansong Shi, Jian Wu, Hailai Ni et al. · 2022 · Signal Transduction and Targeted Therapy
12. An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants
    Hirohito Ishigaki, Fumihiko Yasui, Misako Nakayama, Akinori Endo, Naoki Yamamoto, Kenzaburo Yamaji, Cong Thanh Nguyen, Yoshinori Kitagawa, Takahiro Sanada, Tomoko Honda et al. · 2022 · Frontiers in Microbiology
13. COVID-19’s immuno-pathology and cardiovascular diseases
    Entezar Mehrabi Nasab, Hassan Aghajani, Reza Hassanzadeh Makoui, Seyyed Shamsadin Athari · 2023 · Journal of Investigative Medicine
14. Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication
    Daseuli Yu, Hee-Jeong Han, Jeonghye Yu, Jihye Kim, Gun‐Hee Lee, Ju-Hee Yang, Byeong-Min Song, Dongseob Tark, Byeong‐Sun Choi, Sangmin Kang et al. · 2023 · Molecular Therapy
15. Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
    James A. Williams, Marco Biancucci, Laura N. Lessen, Sai Tian, Ankita Balsaraf, Lynn Chen, Chelsy C. Chesterman, Giulietta Maruggi, Sarah Vandepaer, Ying Huang et al. · 2023 · Science Advances
16. Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
    Scott A. McConnell, Jaiprasath Sachithanandham, Nathan J. Mudrak, Xianming Zhu, Parsa Alba Farhang, Radamés J. B. Cordero, Maggie P. Wear, Janna R. Shapiro, Han-Sol Park, Sabra L. Klein et al. · 2023 · Cell chemical biology
17. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain
    Yanqun Wang, Zhaoyong Zhang, Minnan Yang, Xinyi Xiong, Qihong Yan, Lei Cao, Peilan Wei, Yuting Zhang, Lu Zhang, Kexin Lv et al. · 2024 · Cell Reports
18. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
    Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Armando Camacho, C. Alméciga-Díaz, Cesar A. Ramirez-Segura · 2024 · Heliyon
19. Biophysical principles predict fitness of SARS-CoV-2 variants
    Dianzhuo Wang, Marian Huot, Vaibhav Mohanty, Eugene I. Shakhnovich · 2024 · Proceedings of the National Academy of Sciences
20. Antibody therapies for the treatment of COVID-19
    Zhiqiang Ku, Xiaohua Ye, Georgina To’a Salazar, Ningyan Zhang, Zhiqiang An · 2020 · Antibody Therapeutics
21. Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2
    Francesca Fagiani, Michele Catanzaro, Cristina Lanni · 2020 · Signal Transduction and Targeted Therapy
22. Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis
    Li Zhang, Binyang Zheng, Xingsu Gao, Libo Zhang, Hongxin Pan, Yong Qiao, Guangli Suo, Fengcai Zhu · 2020 · Frontiers in Immunology
23. Endothelial cell, myeloid, and adaptive immune responses in SARS‐CoV‐2 infection
    Nicolas Degauque, Alain Haziot, Sophie Brouard, Nuala Mooney · 2021 · The FASEB Journal
24. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization
    Nicholas Wohlgemuth, Kendall T. Whitt, Sean Cherry, Ericka Kirkpatrick Roubidoux, Chun-Yang Lin, Kim Allison, Ashleigh Gowen, Pamela J. Freiden, Emma Kaitlynn Allen, St. Jude Investigative Team et al. · 2021 · Microbiology Spectrum
25. A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program
    Vijay Rani Rajpal, Shashi K. Sharma, D. Sehgal, Apekshita Singh, Avinash Kumar, S. Vaishnavi, M. Tiwari, Hemal Bhalla, S. Goel, S. Raina · 2022 · Future Virology
26. Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test
    Ying Zhang, Yixiao Chen, Yong He, Yizhe Li, Xiaoli Zhang, Jiajie Liang, Jinyong He, Shaofang Lü, Zhixing Gao, Jianhua Xu et al. · 2022 · Talanta
27. High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters
    Yusuke Higuchi, Tatsuya Suzuki, Takao Arimori, Nariko Ikemura, Emiko Mihara, Yuhei Kirita, Eriko Ohgitani, Osam Mazda, Daisuke Motooka, Shota Nakamura et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
28. Correction to “Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys”
    Heng Li, Lei Guo, Huiwen Zheng, Jing Li, Xin Zhao, Jiaqi Li, Yan Liang, Fengmei Yang, Yurong Zhao, Jinling Yang et al. · 2021 · Bioconjugate Chemistry
29. RETRACTED: Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19
    Jelili Olaide Mustapha, Idris Nasir Abdullahi, Oluwabusola Ajagbe, Anthony Uchenna Emeribe, Samuel Ayobami Fasogbon, Solomon Oloche Onoja, Charles Egede Ugwu, Chikodi Modesta Umeozuru, Folake Olubunmi Ajayi, Wudi Natasha Tanko et al. · 2021 · Heliyon · Retracted
30. The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients
    Dominika Dęborska−Materkowska, Dorota Kamińska · 2021 · Viruses
31. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization
    Haijun Tang, Long Gao, Zhao Wu, Fang Meng, Xin Zhao, Yun Shao, Guocun Hou, Xiaohong Du, Frank Xiao-Feng Qin · 2022 · Frontiers in Immunology
32. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering
    Gennady M. Verkhivker · 2022 · International Journal of Molecular Sciences
33. Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology
    Qing Bao, Tao Yang, Mingying Yang, Chuanbin Mao · 2022 · Open Research (University of Surrey)
34. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift
    Adrien Laroche, María Lucía Orsini Delgado, Benjamin Chalopin, Philippe Cuniasse, Steven G. DuBois, Raphaël Sierocki, Fabrice Gallais, Stéphanie Debroas, Laurent Bellanger, Stéphanie Simon et al. · 2022 · mAbs
35. Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
    M. Bhattacharya, S. Chatterjee, Bidyut Mallik, A. R. Sharma, C. Chakraborty · 2022 · Vaccines
36. Semisynthesis of homogeneous spike RBD glycoforms from SARS-CoV-2 for profiling the correlations between glycan composition and function
    Farong Ye, Cheng Li, Feng‐Liang Liu, Xinliang Liu, Peng Hui Xu, Rong‐Hua Luo, Wenping Song, Yong‐Tang Zheng, Tianlei Ying, Biao Yu et al. · 2024 · National Science Review
37. The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
    Qiudong Su, Yi Yao, Ye-ning Zou, Zhi-yuan Jia, Feng Qiu, Feng Wang, Wenjiao Yin, Wen-ting Zhou, Shuang Zhang, Peng-cheng Yu et al. · 2020 · Vaccine
38. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
    Youjia Guo, Atsushi Kawaguchi, Masaru Takeshita, Takeshi Sekiya, Mikako Hirohama, Akio Yamashita, the Keio Donner Project, Haruhiko Siomi, Kensaku Murano · 2021 · Journal of Biological Chemistry
39. Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression
    M. Cohen, D. Wohl, William A. Fischer, David Smith, J. Eron · 2021 · Clinical Infectious Diseases
40. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution
    Huan Qi, Ming‐liang Ma, He‐wei Jiang, Jianya Ling, Lingyun Chen, Hainan Zhang, Dan‐yun Lai, Yang Li, Ziwen Guo, Chuansheng Hu et al. · 2021 · Cellular and Molecular Immunology
41. Rapid and High‐Throughput SARS‐CoV‐2 RNA Detection without RNA Extraction and Amplification by Using a Microfluidic Biochip
    Yujin Chu, Jiaoyan Qiu, Yihe Wang, Min Wang, Yu Zhang, Lin Ge Han · 2022 · Chemistry - A European Journal
42. Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations
    Gennady M. Verkhivker, Steve Agajanian, Ryan Kassab, Keerthi Krishnan · 2022 · International Journal of Molecular Sciences
43. SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
    Masaud Shah, Sung Ung Moon, Jang Hyun Kim, Trinh Thanh Thao, Hyun Goo Woo · 2022 · Computational and Structural Biotechnology Journal
44. Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein
    Yu-Lei Chen, Jin-Jin Lin, Huan Ma, Ning Zhong, Xin-Xin Xie, Yunru Yang, Pei-Yi Zheng, Ling-Jing Zhang, Teng-Chuan Jin, M. Cao · 2022 · International Journal of Molecular Sciences
45. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
    Mingtao Liu, Hui Gan, Zhi-Man Liang, Li Liu, Qi-Wen Liu, Yiyin Mai, Hui-Huang Chen, Baoying Lei, Shangwei Yu, Hui-Hui Chen et al. · 2023 · Frontiers in Microbiology
46. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
    Roxie C. Girardin, Alan P. Dupuis, Anne F. Payne, Timothy J Sullivan, Donna Strauss, Monica M. Parker, Kathleen A. McDonough · 2020 · The Journal of Infectious Diseases
47. Gathering, processing, and interpreting information about COVID-19
    Arnout B. Boot, Anita Eerland, Joran Jongerling, Peter P. J. L. Verkoeijen, Rolf Antonius Zwaan · 2021 · Scientific Reports
48. Analysis of the molecular mechanism of SARS-CoV-2 antibodies
    Dongfu Jin, Jing Wei, Jian Sun · 2021 · Biochemical and Biophysical Research Communications
49. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner
    Fatima Amanat, Shirin Strohmeier, Wen-Hsin Lee, Sandhya Bangaru, Andrew B. Ward, Lynda Coughlan, Florian Krammer · 2021 · mBio
50. Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives
    Cassiano Martin Batista, Leonardo Foti · 2021 · International Immunopharmacology
51. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report
    Olivera Lijeskić, Ivana Klun, Marija Stamenov Djaković, Nenad Gligorić, Tijana Štajner, Jelena Srbljanović, Olgica Djurković–Djaković · 2021 · Vaccines
52. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
    Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, Sandra E. Esparon, Ester López, Klasina Chappin, Li‐Jin Chan, Francesca L. Mordant, Wen Shi Lee, Nicholas A. Gherardin et al. · 2022 · Frontiers in Immunology
53. Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development
    Xiao-Huan Liu, Ting Cheng, Baoyu Liu, Jia Chi, Ting Shu, Tao Wang · 2022 · Frontiers in Pharmacology
54. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
    Zhiyang Ling, Chunyan Yi, Xiaoyu Sun, Zhuo Yang, Bing Sun · 2022 · Science China Life Sciences
55. SARS-CoV-2-specific T cell and humoral immunity in individuals with and without HIV in an African population: a prospective cohort study
    Owen Ngalamika, Salum J. Lidenge, Marie Claire Mukasine, Musonda Kawimbe, Patrick Kamanzi, John R. Ngowi, Julius David Mwaiselage, For Yue Tso · 2022 · International Journal of Infectious Diseases
56. Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant
    K. Gayvert, S. McKay, W. Lim, Alina Baum, Christos A. Kyratsous, R. Copin, G. Atwal · 2023 · Npj viruses
57. Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
    Alex L. Roederer, Yi Cao, Kerri St. Denis, Maegan L. Sheehan, Chia Jung Li, Evan Christopher Lam, David J. Gregory, Mark C. Poznansky, Anthony John Iafrate, David H. Canaday et al. · 2024 · Cell Reports Medicine
58. Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19
    Waquar Ahsan, Hassan A. Alhazmi, Kuldeep Patel, Bharti Mangla, Mohammed Al Bratty, Shamama Javed, Asim Najmi, Muhammad H. Sultan, Hafiz Antar Makeen, Asaad Khalid et al. · 2020 · Frontiers in Public Health
59. A Review on Currently Available Potential Therapeutic Options for COVID-19
    Solmaz Ohadian Moghadam · 2020 · International Journal of General Medicine
60. Advances in emergent biological recognition elements and bioelectronics for diagnosing COVID-19
    Praopim Limsakul, Krit Charupanit, Chochanon Moonla, Itthipon Jeerapan · 2021 · Emergent Materials
61. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
    Sicong Yu, Keda Chen, Lei Fang, Haiyan Mao, Xiuyu Lou, Chaonan Li, Yanjun Zhang · 2021 · Vaccines
62. SARS-CoV-2 receptor-binding mutations and antibody contact sites
    Marios Mejdani, Kiandokht Haddadi, Chester Pham, Radhakrishnan Mahadevan · 2021 · Antibody Therapeutics
63. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
    Belén Aparicio, Noëlia Casares, Josune Egea, Marta Ruiz, Diana Llópiz, Sheila Maestro, Cristina Olagüe, Gloria González‐Aseguinolaza, Cristian Smerdou, Ascensión López-Dı́az de Cerio et al. · 2021 · Emerging Microbes & Infections
64. Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
    Mohamed A Hendy, Samuel Kaufman, Mauricio Rene Ponga · 2021 · Scientific Reports
65. Magnetofluid-Integrated Multicolor Immunochip for Visual Analysis of Neutralizing Antibodies to SARS-CoV-2 Variants
    Haicong Shen, Xinying Chen, Liuqing Zeng, Xing Jun Xu, Yingzhou Tao, Siyin Kang, Yinzhu Lu, Mingjian Lian, Chaoyong James Yang, Zhi Zhu · 2022 · Analytical Chemistry
66. Peptide–Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants
    Jonathan M. Labriola, Shane Miersch, Gang Chen, Chao Chen, Alevtina Pavlenco, Reza Saberianfar, Francesca Caccuri, Alberto Zani, Nitin Sharma, Annie Feng et al. · 2022 · ACS Chemical Biology
67. Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
    Douglas F. Lake, Alexa J. Roeder, María J. González‐Moa, Megan A. Koehler, Erin J. Kaleta, Paniz Jasbi, John Vanderhoof, Davis McKechnie, Jack Forman, Baylee A. Edwards et al. · 2022 · Communications Medicine
68. Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination
    Furong Qi, Yingyin Cao, Shuye Zhang, Zheng Zhang · 2022 · Frontiers in Immunology
69. Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
    Xiaoying Zhou, Huixia Lu, Miaomiao Sang, Shanhu Qiu, Yang Yuan, Tongzhi Wu, Junhao Chen, Zilin Sun · 2023 · Human Vaccines & Immunotherapeutics
70. Biological therapeutic modalities
    Munish Chhabra · 2021 · Elsevier eBooks
71. Independent acquisition of short insertions at the RIR1 site in the spike N‐terminal domain of the SARS‐CoV‐2 BA.2 lineage
    Samuele Greco, Marco Gerdol · 2022 · Transboundary and Emerging Diseases
72. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations
    Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abasi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
73. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19
    Thomas Lung, Michel Daniel Kazatchkine, Lorenz Risch, Martin Risch, Urs E. Nydegger · 2020 · Transfusion and Apheresis Science
74. The Immune Responses against Coronavirus Infections: Friend or Foe?
    Arefe Vafaeinezhad, Mohammad Reza Atashzar, Rasoul Baharlou · 2021 · International Archives of Allergy and Immunology
75. Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy
    Z. Cheng, Bi-Zhou Li, Zhi-Qing Zhan, Zi-Fan Zhao, Ming-Shan Xue, P. Zheng, Jiali Lyu, Chundi Hu, Jian-Xing He, Ru-Chong Chen et al. · 2022 · Clinical reviews in allergy and immunology
76. Advances in antibody discovery from human BCR repertoires
    Zichang Xu, Hendra Saputra Ismanto, Hao Zhou, Dianita S. Saputri, Fuminori Sugihara, Daron M. Standley · 2022 · Frontiers in Bioinformatics
77. Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
    Pradeepa Pushparaj, Andrea Nicoletto, Xaquín Castro Dopico, Daniel J. Sheward, Sungyong Kim, Simon Ekström, Ben Murrell, Martin Corcoran, Gunilla B. Karlsson Hedestam · 2023 · Frontiers in Virology
78. State of the Art in Epitope Mapping and Opportunities in COVID-19
    Samira M. Hamed, Masarra M. Sakr, Ghadir S. El-Housseiny, Reham Wasfi, Khaled M. Aboshanab · 2023 · Future Science OA
79. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
    Xuehua Yang, Huarui Duan, Xiuying Liu, Xinhui Zhang, Shengnan Pan, Fangyuan Zhang, Peixiang Gao, Бо Лю, Jian Yang, Xiaojing Chi et al. · 2023 · Journal of Virology
80. Can antibodies be “vegan”? A guide through the maze of today’s antibody generation methods
    Stefan Dübel · 2024 · mAbs
81. Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1
    Zhou Tong, Jianyu Tong, Wenwen Lei, Yufeng Xie, Yingzi Cui, Guowen Jia, Shihua Li, Zezhong Zhang, Zhimin Cheng, Xiao Xing et al. · 2024 · Cell Reports
82. Supramolecular Architectures of Dendritic Polymers Provide Irreversible Inhibitor to Block Viral Infection
    Ehsan Mohammadifar, Matteo Gasbarri, Mathias Dimde, Chuanxiong Nie, Heyun Wang, Tatyana L. Povolotsky, Yannic Kerkhoff, Daniel J.-M. Desmecht, Sylvain François Prévost, Thomas N. Zemb et al. · 2024 · Advanced Materials
83. Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?
    Muki Shehu Shey, Joseph Okeibunor, Ali Ahmed Yahaya, Belinda Louise Herring, Oyewale Tomori, Sheick Oumar Coulibaly, Hieronyma Nelisiwe Gumede-Moeletsi, Jason Mathiu Mwenda, Zabulon Yoti, Charles Shey Wiysonge et al. · 2020 · PubMed Central
84. The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review
    Sarah Makram Elsayed, Mithun K Reddy, Pooja M Murthy, Ishita Gupta, Monika Valiuskyte, Diana F. Sánchez-Velazco, Mark Anthony Diaz · 2020 · Cureus
85. Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2
    Н. В. Антипова, Tatyana D. Larionova, Andrei E. Siniavin, Maria A. Nikiforova, Vladimir А. Gushchin, И И Бабиченко, Alexey V. Volkov, Michail I. Shakhparonov, Marat S. Pavlyukov · 2020 · International Journal of Molecular Sciences
86. Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS‐CoV‐2): Challenges to Near‐Future Breakthroughs
    Juliana Gil Melgaço, Danielle Brito e Cunha, Tamiris Azamor, Andréa Marques Vieira da Silva, Luciana Neves Tubarão, Rafael Braga Gonçalves, Robson Q. Monteiro, Sotiris Missailidis, Patrícia Neves, Ana Paula Dinis Ano Bom · 2020 · Journal of Immunology Research
87. Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?
    Yalçın Pısıl, Zafer Yazıcı, Hisatoshi Shida, Tomoyuki Miura · 2021 · Pathogens
88. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity
    A. Olia, Y. Tsybovsky, Steven J. Chen, Cui-Ping Liu, A. Nazzari, Li Ou, Ling-Shu Wang, W. Kong, Kwan Leung, Tracy Liu et al. · 2021 · Journal of Biological Chemistry
89. Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2
    Tao Wang, Xiaocui Fang, Tao Wen, Jian Liu, Zhaoyi Zhai, Zhiyou Wang, Jie Meng, Yanlian Yang, Chen Wang, Haiyan Xu · 2021 · Journal of Medicinal Chemistry
90. Potential metal‐related strategies for prevention and treatment of COVID‐19
    Yaqiong Ni, Huihui Zeng, Xianwen Song, Jun Zheng, Hui‐Qiong Wu, Chuntai Liu, Yi Zhang · 2022 · Rare Metals
91. Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD
    Denis Kolesov, Maria V. Sinegubova, Lutsia K. Dayanova, Inna V. Dolzhikova, Ivan Ivanovich Vorobiev, Nadezhda A. Orlova · 2022 · Diagnostics
92. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection
    Amy J. Schuh, Panayampalli Subbian Satheshkumar, Stephanie Dietz, Lara Bull–Otterson, Myrna D. Charles, Chris Edens, Jefferson M. Jones, Kristina L. Bajema, Kristie E.N. Clarke, L. Clifford McDonald et al. · 2022 · Microbiology Spectrum
93. The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
    Aline Almeida-Oliveira, Diana Praia Borges Freire, Ana Rodrigues de Andrade, Amanda de Miranda Marques, Luciana da Silva Madeira, Jose Procopio Moreno Senna, Ivna Alana Freitas Brasileiro da Silveira, Beatriz de Castro Fialho · 2023 · Journal of Pharmaceutical Innovation
94. Peptides and peptidomimetics as therapeutic agents for Covid‐19
    Achyut Dahal, Jafrin Jobayer Sonju, Konstantin Gus Kousoulas, Seetharama D. S. Jois · 2021 · Peptide Science
95. Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19
    Jennifer A. Juno, Hyon‐Xhi Tan, Wen Shi Lee, Arnold Reynaldi, Hannah G. Kelly, Kathleen M. Wragg, Robyn Esterbauer, Helen E. Kent, C. Jane Batten, Francesca L. Mordant et al. · 2020 · medRxiv
96. Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses
    Shelley Klompus, Sigal Leviatan, Thomas J. Vogl, Iris N. Kalka, Anastasia Godneva, Eilat Shinar, Adina Weinberger, Eran Segal · 2020 · medRxiv
97. Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
    Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen R. Wagstaffe et al. · 2020 · SSRN Electronic Journal
98. Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
    N. C. Dalvie, Sergio A. Rodriguez-Aponte, B. Hartwell, Lisa H. Tostanoski, Andrew M. Biedermann, Laura E. Crowell, K. Kaur, Ozan S. Kumru, L. Carter, Jing-You Yu et al. · 2021 · bioRxiv
99. Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2
    D. Singh, Ihn Han, E. Choi, D. Yadav · 2020 · Computational and Structural Biotechnology Journal
100. Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19
     Tomoyuki Yamaguchi, Toshie Shinagawa, Hisanobu Kobata, Hidemitsu Nakagawa · 2021 · International Journal of Infectious Diseases